PL374431A1 - Kompozycje i sposoby dla działania terapeutycznego - Google Patents
Kompozycje i sposoby dla działania terapeutycznegoInfo
- Publication number
- PL374431A1 PL374431A1 PL03374431A PL37443103A PL374431A1 PL 374431 A1 PL374431 A1 PL 374431A1 PL 03374431 A PL03374431 A PL 03374431A PL 37443103 A PL37443103 A PL 37443103A PL 374431 A1 PL374431 A1 PL 374431A1
- Authority
- PL
- Poland
- Prior art keywords
- compositions
- methods
- therapeutic treatment
- therapeutic
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18902502A | 2002-07-01 | 2002-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL374431A1 true PL374431A1 (pl) | 2005-10-17 |
Family
ID=29999592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03374431A PL374431A1 (pl) | 2002-07-01 | 2003-06-30 | Kompozycje i sposoby dla działania terapeutycznego |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1551452A4 (pl) |
| JP (1) | JP2005534679A (pl) |
| KR (1) | KR20050059001A (pl) |
| CN (1) | CN1678348A (pl) |
| AU (1) | AU2003279657A1 (pl) |
| BR (1) | BR0312484A (pl) |
| CA (1) | CA2491427A1 (pl) |
| IL (1) | IL166062A0 (pl) |
| MX (1) | MXPA05000271A (pl) |
| PL (1) | PL374431A1 (pl) |
| RU (1) | RU2005101622A (pl) |
| WO (1) | WO2004002528A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539235A2 (en) | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| JP2007530603A (ja) * | 2004-03-30 | 2007-11-01 | デン コンゲリク ベテリネル−オク ランドボホイスコレ | プロテアーゼ阻害物質の遮断又は検出による癌治療及び癌治療効能予測の改善 |
| PL1737428T3 (pl) * | 2004-03-31 | 2018-03-30 | University Of Utah Research Foundation | Makrocząsteczkowe systemy dostarczania do nieinwazyjnego obrazowania, oceny i leczenia zapalenia stawów i innych chorób zapalnych |
| KR20080056167A (ko) | 2005-09-26 | 2008-06-20 | 메다렉스, 인코포레이티드 | 씨디70에 대한 인간 모노크로날 항체 |
| RU2366434C1 (ru) * | 2007-12-07 | 2009-09-10 | Институт неорганической химии им. А.В. Николаева Сибирского отделения Российской Академии наук | Гексаядерные кластерные комплексы рения на основе радиоактивных изотопов, обладающие противоопухолевыми свойствами |
| CA2747154C (en) * | 2008-12-19 | 2015-11-10 | Philogen S.P.A. | Immunocytokines for tumour therapy with chemotherapeutic agents |
| CN102116554A (zh) | 2010-01-04 | 2011-07-06 | Lg电子株式会社 | 电冰箱 |
| CN106659784B (zh) | 2014-07-08 | 2022-03-29 | 桑福德伯纳姆医学研究所 | Psgl-1调控剂及其用途 |
| RU2766000C2 (ru) | 2016-01-08 | 2022-02-07 | АльтруБио Инк. | Четырехвалентные антитела к psgl-1 и их применения |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05244987A (ja) * | 1992-02-28 | 1993-09-24 | Unitika Ltd | 抗硫酸化チロシン抗体,その製造方法及び抗硫酸化チロシンモノクローナル抗体を産生するハイブリドーマ |
| US6106834A (en) * | 1993-06-02 | 2000-08-22 | Research Corporation Technologies, Inc. | Use of anti-CD45 leukocyte antigen antibodies for immunomodulation |
| EP1098665B9 (en) * | 1998-07-13 | 2003-08-13 | The Board Of Regents, The University Of Texas System | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| AU774419C (en) * | 1998-10-30 | 2005-03-03 | Genetics Institute, Llc | Inhibition of differentiation of cytotoxic T-cells by P-selectin ligand (PSGL) antagonists |
| EP1284751A1 (en) * | 2000-05-11 | 2003-02-26 | National Tsing Hua University | Compositions and methods for induction of active autoimmunity |
| EA005931B1 (ru) * | 2000-05-15 | 2005-08-25 | Фармация Италия С.П.А. | Ингибиторы ароматазы и моноклональные антитела против her2 как противоопухолевые агенты |
| HUP0700079A2 (en) * | 2000-12-29 | 2007-05-02 | Savient Pharmaceuticals | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| CA2433227A1 (en) * | 2000-12-29 | 2002-08-01 | Bio-Technology General, Inc. | Specific human antibodies for selective cancer therapy |
-
2003
- 2003-06-30 RU RU2005101622/15A patent/RU2005101622A/ru not_active Application Discontinuation
- 2003-06-30 BR BRPI0312484-3A patent/BR0312484A/pt not_active IP Right Cessation
- 2003-06-30 CA CA002491427A patent/CA2491427A1/en not_active Abandoned
- 2003-06-30 EP EP03742338A patent/EP1551452A4/en not_active Withdrawn
- 2003-06-30 AU AU2003279657A patent/AU2003279657A1/en not_active Abandoned
- 2003-06-30 MX MXPA05000271A patent/MXPA05000271A/es unknown
- 2003-06-30 CN CNA03820441XA patent/CN1678348A/zh active Pending
- 2003-06-30 WO PCT/US2003/020604 patent/WO2004002528A1/en not_active Ceased
- 2003-06-30 PL PL03374431A patent/PL374431A1/pl not_active Application Discontinuation
- 2003-06-30 KR KR1020047021602A patent/KR20050059001A/ko not_active Withdrawn
- 2003-06-30 JP JP2004518133A patent/JP2005534679A/ja active Pending
-
2004
- 2004-12-30 IL IL16606204A patent/IL166062A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1551452A4 (en) | 2006-08-30 |
| WO2004002528A1 (en) | 2004-01-08 |
| KR20050059001A (ko) | 2005-06-17 |
| RU2005101622A (ru) | 2006-01-27 |
| CN1678348A (zh) | 2005-10-05 |
| IL166062A0 (en) | 2006-01-15 |
| BR0312484A (pt) | 2008-01-08 |
| AU2003279657A1 (en) | 2004-01-19 |
| EP1551452A1 (en) | 2005-07-13 |
| MXPA05000271A (es) | 2005-03-31 |
| CA2491427A1 (en) | 2004-01-08 |
| WO2004002528A9 (en) | 2004-11-18 |
| JP2005534679A (ja) | 2005-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0201850D0 (en) | Therapeutic treatment | |
| GB0216321D0 (en) | Therapeutic treatment | |
| IL172194A0 (en) | Methods and compositions for treating amyloid-related diseases | |
| GB0316912D0 (en) | Therapeutic treatment | |
| AU2003278775A8 (en) | Porifera-based therapeutic compositions for treating and preventing skin diseases | |
| GB0320806D0 (en) | Therapeutic treatment | |
| AU2003287443A8 (en) | Compositions and methods for pain reduction | |
| SI1545256T1 (sl) | Naprava za terapevtsko zdravljenje | |
| GB0223367D0 (en) | Therapeutic treatment | |
| GB0303609D0 (en) | Novel therapeutic method and compositions | |
| AU2003232044A8 (en) | Composition and method for dermatological treatment | |
| GB0223854D0 (en) | Therapeutic treatment | |
| IL166062A0 (en) | Compositions and methods for therapeutic treatment | |
| GB0210464D0 (en) | Therapeutic treatment | |
| EP1569928A4 (en) | THERAPEUTIC COMPOUNDS AND METHOD | |
| AU2003275433A8 (en) | Compositions and methods for treating pain | |
| GB0307863D0 (en) | Therapeutic treatment | |
| AU2003291730A8 (en) | Methods and compositions for treating neurodegenerative diseases | |
| GB0327050D0 (en) | Therapeutic methods compositions and uses | |
| EP1583543A4 (en) | METHOD AND THERAPEUTIC COMPOSITIONS IN THE TREATMENT OF ADVANCED CARCINOMA | |
| GB0313772D0 (en) | Therapeutic treatment | |
| GB0303600D0 (en) | Novel therapeutic method and compositions | |
| GB0221712D0 (en) | Methods of treatment | |
| GB0205826D0 (en) | Therapeutic compositions and methods | |
| IL163878A0 (en) | Compositions and methods for treating mdma-inducedtoxicity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |